NOVOCURE LTD (NVCR:NASDAQ)
$13.02 0.79 (6.4595%)
Analysed NOVOCURE LTD (NVCR:NASDAQ) News Sources
NovoCure (NVCR) Is Down 6.6% After Strong PANOVA-4 Phase 2 Data In Metastatic Pancreatic Cancer – Has The Bull Case Changed?
02-04-2026
yahoo.com
Novocure to Report First Quarter 2026 Financial Results
01-04-2026
yahoo.com
Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates
27-03-2026
yahoo.com
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Ongoing Middle East Tensions
26-03-2026
yahoo.com
Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
26-03-2026
yahoo.com
Is NovoCure (NVCR) Now Pricing In Too Much Pessimism After Prolonged Share Price Slump
26-03-2026
yahoo.com
LENZ Therapeutics, Inc. (LENZ) Reports Q4 Loss, Misses Revenue Estimates
24-03-2026
yahoo.com
Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment
09-03-2026
yahoo.com
NovoCure (NVCR) Reliance on International Sales: What Investors Need to Know
02-03-2026
yahoo.com
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
02-03-2026
yahoo.com
What is the current price of NOVOCURE LTD (NVCR:NASDAQ)?
The current price of NOVOCURE LTD (NVCR:NASDAQ) is $13.02.
NOVOCURE LTD (NVCR:NASDAQ) absolute price change since previous trading day?
The absolute price change of NOVOCURE LTD (NVCR:NASDAQ) since the previous trading day is $0.79.
NOVOCURE LTD (NVCR:NASDAQ) percentage price change since previous trading day?
The percentage price change of NOVOCURE LTD (NVCR:NASDAQ) since the previous trading day is 6.4595%.
What is the most recent average sentiment score for NOVOCURE LTD (NVCR:NASDAQ)?
The most recent average sentiment score for NOVOCURE LTD (NVCR:NASDAQ) is 69 out of 100.
What is the most recent average sentiment for NOVOCURE LTD (NVCR:NASDAQ)?
The most recent sentiment for NOVOCURE LTD (NVCR:NASDAQ) is .
SEC-8K** Filing Available For NOVOCURE LTD (NVCR:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.